Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus methotrexate in pediatric chronic plaque psoriasis
NL-OMON37563Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab and methotrexate in plaque psoriasis and psoriasis (3 arms), sponsored by AbbVie Inc. Primary endpoints: PASI 75 response at Week 16a and PGA 0 or 1 at Week 16a. Started Sep 2012; status: active, not recruiting.
02
Drugs
adalimumabmethotrexate
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NL-OMON37563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37563.